News | September 29, 2025
Amgen invests $650 million on expansion of US manufacturing network
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
The new site enables end-to-end production of viral vector gene therapies
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
BIL also holds an option to increase its equity stake by an additional 15%
The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Subscribe To Our Newsletter & Stay Updated
